| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EFNA2 |
| Uniprot No | O43921 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-213aa |
| 氨基酸序列 | MAPAQRPLLPLLLLLLPLPPPPFARAEDAARANSDRYAVYWNRSNPRFHA GAGDDGGGYTVEVSINDYLDIYCPHYGAPLPPAERMEHYVLYMVNGEGHA SCDHRQRGFKRWECNRPAAPGGPLKFSEKFQLFTPFSLGFEFRPGHEYYY ISATPPNAVDRPCLRLKVYVRPTNETLYEAPEPIFTSNNSCSSPGGCRLF LSTIPVLWTLLGS |
| 预测分子量 | 50 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EFNA2重组蛋白的3篇参考文献的简要信息：
---
1. **标题**: *Ephrin-A2 promotes prostate cancer metastasis through VEGF-mediated angiogenesis*
**作者**: Xin H, et al.
**摘要**: 该研究通过重组EFNA2蛋白体外实验，发现其通过激活VEGF信号通路促进血管生成，增强前列腺癌细胞的侵袭和转移能力，提示EFNA2可作为抗肿瘤治疗的潜在靶点。
---
2. **标题**: *Recombinant Ephrin-A2 protein induces endothelial cell sprouting in vitro*
**作者**: Wang Y, et al.
**摘要**: 研究利用大肠杆菌表达系统制备重组EFNA2蛋白，证明其能显著诱导内皮细胞管状结构形成，并激活Eph受体下游的MAPK信号通路，为研究EFNs在血管发育中的作用提供工具。
---
3. **标题**: *EFNA2 recombinant protein attenuates neuroinflammation via EphA4 receptor interaction*
**作者**: Li J, et al.
**摘要**: 通过哺乳动物细胞表达纯化的重组EFNA2蛋白，在小鼠模型中证实其可通过结合EphA4受体抑制小胶质细胞活化，减轻神经炎症，为神经退行性疾病治疗提供新思路。
---
注：以上文献信息为示例性质，实际文献需通过PubMed、Web of Science等平台检索确认。建议结合具体研究方向补充关键词(如“recombinant expression”、“cancer”、“angiogenesis”)进一步筛选。
**Background of EFNA2 Recombinant Protein**
Ephrin-A2 (EFNA2) is a member of the ephrin family, which comprises membrane-bound or secreted ligands that interact with Eph receptor tyrosine kinases to mediate diverse cellular processes, including cell adhesion, migration, and tissue patterning during development. EFNA2 specifically binds to EphA receptors, triggering bidirectional signaling pathways critical for axon guidance, vascular development, and synaptic plasticity. Dysregulation of EFNA2-EphA interactions has been implicated in pathologies such as cancer metastasis, neurodegenerative disorders, and cardiovascular diseases.
Recombinant EFNA2 protein is engineered *in vitro* using expression systems (e.g., mammalian, insect, or bacterial cells) to produce a purified, bioactive form of the ligand. This protein typically retains the functional Eph receptor-binding domain, enabling researchers to study EFNA2-mediated signaling without the complexity of cell membrane-associated ephrins. It is widely used in assays to investigate receptor-ligand interactions, downstream signaling cascades (e.g., MAPK/ERK or PI3K/AKT pathways), and EFNA2's role in modulating cell behavior *in vitro* or *in vivo*.
In cancer research, EFNA2 recombinant protein has revealed dual roles—acting as either a tumor suppressor or promoter depending on context—by influencing angiogenesis, epithelial-mesenchymal transition (EMT), and immune responses. It also holds potential as a therapeutic target or diagnostic biomarker. Recent studies explore its utility in tissue engineering and regenerative medicine, leveraging its ability to guide neuronal or vascular growth. Despite progress, challenges remain in understanding context-dependent signaling outcomes and optimizing recombinant EFNA2 for clinical applications.
×
